Gamida Cell is a cell therapy company focuses on finding cures for blood cancers and serious blood diseases. Co.'s product candidate, omidubicel, is an investigational cell therapy designed to expand the life-saving benefits of hematopoietic stem cell (bone marrow) transplant. Co. is also developing omidubicel for the treatment of other rare, life-threatening hematologic diseases, including severe aplastic anemia, a bone marrow failure disease. Co. is also applying its technology to develop GDA-201 for innate immunotherapy of expanded natural killer cells for application in additional cancer indications when combined with standard-of-care antibody therapies. The GMDA stock yearly return is shown above.
The yearly return on the GMDA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GMDA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|